Pamidronic acid
Product Sizes
100 mg
£ POA
HY-B0012-100MG
25 mg
£ POA
HY-B0012-25MG
50 mg
£ POA
HY-B0012-50MG
10mM/1mL
£ POA
HY-B0012-10MM
About this Product
- SKU:
- HY-B0012
- Application:
- Antibody Microarray
- CAS Number:
- 40391-99-9
- Extra Details:
- Pamidronic acid; the second-generation nitrogen-containing bisphosphonate; is an inhibitor of bone loss. Pamidronic acid significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone; and inhibiting the expression of RANKL and MMP-9 in both tissues; as well as TLR-4 in cartilage; thereby alleviating cartilage degeneration. Additionally; Pamidronic acid can inhibit the signaling of Wnt and β-catenin; and is applicable for research on osteoporosis and osteosarcoma[1][2][3][4].
- Molecular Weight:
- 235.07
- Purity:
- 99.05
- References:
- [1]Ashton JA, et al. Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cellsfrom dogs. Am J Vet Res. 2005 May;66(5):885-92.|[2]Xu Y, et al. Pamidronate Disodium Leads to Bone Necrosis via Suppression of Wnt/β-Catenin Signaling in Human Bone Marrow Mesenchymal Stem Cells In Vitro. J Oral Maxillofac Surg. 2017 Mar 23.|[3]Lv Y, et al. Effects of pamidronate disodium on the loss of osteoarthritic subchondral bone and the expression of cartilaginous and subchondral osteoprotegerin and RANKL in rabbits. BMC Musculoskelet Disord. 2014 Nov 6;15:371.|[4]Kovacs R, et al. The synthesis of pamidronic derivatives in different solvents: An optimization and a mechanistic study[J]. Heteroatom Chemistry, 2014, 25(3): 186-194.
- Research Area:
- Cancer; Metabolic Disease; Inflammation/Immunology
- Shipping Conditions:
- Blue Ice
- Storage Conditions:
- -20[o]C (Powder; protect from light)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- Immunology/Inflammation;NF-κB;Stem Cell/Wnt
